The University of Chicago Header Logo

Connection

Olufunmilayo Olopade to Middle Aged

This is a "connection" page, showing publications Olufunmilayo Olopade has written about Middle Aged.
Connection Strength

10.684
  1. Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer. JAMA Netw Open. 2023 03 01; 6(3):e233329.
    View in: PubMed
    Score: 0.227
  2. Cancer Genetic Services in a Low- to Middle-Income Country: Cross-Sectional Survey Assessing Willingness to Undergo and Pay for Germline Genetic Testing. JCO Glob Oncol. 2023 02; 9:e2100140.
    View in: PubMed
    Score: 0.225
  3. Oncology Training Needs Assessment Among Health Care Professionals in Nigeria. JCO Glob Oncol. 2022 05; 8:e2200017.
    View in: PubMed
    Score: 0.214
  4. Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. Nat Commun. 2021 11 26; 12(1):6946.
    View in: PubMed
    Score: 0.208
  5. Traditional medicine usage among adult women in Ibadan, Nigeria: a cross-sectional study. BMC Complement Med Ther. 2020 Mar 20; 20(1):93.
    View in: PubMed
    Score: 0.185
  6. Infrastructural Challenges Lead to Delay of Curative Radiotherapy in Nigeria. JCO Glob Oncol. 2020 02; 6:269-276.
    View in: PubMed
    Score: 0.183
  7. Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria. Int J Cancer. 2019 12 15; 145(12):3321-3333.
    View in: PubMed
    Score: 0.176
  8. Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk. Fam Cancer. 2018 10; 17(4):495-505.
    View in: PubMed
    Score: 0.167
  9. Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers. Clin Cancer Res. 2019 03 15; 25(6):1786-1794.
    View in: PubMed
    Score: 0.166
  10. Inherited Breast Cancer in Nigerian Women. J Clin Oncol. 2018 10 01; 36(28):2820-2825.
    View in: PubMed
    Score: 0.166
  11. Knowledge of Genetic Counseling Among Patients With Breast Cancer and Their Relatives at a Nigerian Teaching Hospital. J Glob Oncol. 2018 07; 4:1-8.
    View in: PubMed
    Score: 0.164
  12. Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish Individuals. J Genet Couns. 2018 12; 27(6):1405-1410.
    View in: PubMed
    Score: 0.164
  13. Breast Cancer Genetics Knowledge and Testing Intentions among Nigerian Professional Women. J Genet Couns. 2018 08; 27(4):863-873.
    View in: PubMed
    Score: 0.158
  14. Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patients. Oncotarget. 2016 08 23; 7(34):55231-55248.
    View in: PubMed
    Score: 0.144
  15. Breast cancer risk after full-term pregnancies among African women from Nigeria, Cameroon, and Uganda. Cancer. 2015 Jul 01; 121(13):2237-43.
    View in: PubMed
    Score: 0.131
  16. Social barriers to diagnosis and treatment of breast cancer in patients presenting at a teaching hospital in Ibadan, Nigeria. Glob Public Health. 2015; 10(3):331-44.
    View in: PubMed
    Score: 0.128
  17. Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat. 2015 Jan; 149(1):31-9.
    View in: PubMed
    Score: 0.128
  18. Tumor genome analysis includes germline genome: are we ready for surprises? Int J Cancer. 2015 Apr 01; 136(7):1559-67.
    View in: PubMed
    Score: 0.125
  19. Use of Web-based training for quality improvement between a field immunohistochemistry laboratory in Nigeria and its United States-based partner institution. Ann Diagn Pathol. 2013 Dec; 17(6):526-30.
    View in: PubMed
    Score: 0.118
  20. Neo-adjuvant capecitabine chemotherapy in women with newly diagnosed locally advanced breast cancer in a resource-poor setting (Nigeria): efficacy and safety in a phase II feasibility study. Breast J. 2013 Sep-Oct; 19(5):470-7.
    View in: PubMed
    Score: 0.116
  21. Expression and sub-cellular localization of an epigenetic regulator, co-activator arginine methyltransferase 1 (CARM1), is associated with specific breast cancer subtypes and ethnicity. Mol Cancer. 2013 May 10; 12(1):40.
    View in: PubMed
    Score: 0.115
  22. Level of awareness of mammography among women attending outpatient clinics in a teaching hospital in Ibadan, South-West Nigeria. BMC Public Health. 2013 Jan 16; 13:40.
    View in: PubMed
    Score: 0.112
  23. Resistance to trastuzumab in HER2-positive mucinous invasive ductal breast carcinoma. Clin Breast Cancer. 2013 Apr; 13(2):156-8.
    View in: PubMed
    Score: 0.112
  24. Microsatellites in the estrogen receptor (ESR1, ESR2) and androgen receptor (AR) genes and breast cancer risk in African American and Nigerian women. PLoS One. 2012; 7(7):e40494.
    View in: PubMed
    Score: 0.108
  25. Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry. Breast Cancer Res Treat. 2012 Jul; 134(2):889-94.
    View in: PubMed
    Score: 0.108
  26. Body fat distribution and breast cancer risk: findings from the Nigerian breast cancer study. Cancer Causes Control. 2012 Apr; 23(4):565-74.
    View in: PubMed
    Score: 0.106
  27. Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis. 2012 Apr; 33(4):835-40.
    View in: PubMed
    Score: 0.106
  28. High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J Cancer. 2012 Sep 01; 131(5):1114-23.
    View in: PubMed
    Score: 0.105
  29. Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res. 2012 Jan 15; 18(2):350-9.
    View in: PubMed
    Score: 0.104
  30. Novel germline PALB2 truncating mutations in African American breast cancer patients. Cancer. 2012 Mar 01; 118(5):1362-70.
    View in: PubMed
    Score: 0.102
  31. Concordance in histological and biological parameters between first and second primary breast cancers. Cancer. 2011 Mar 01; 117(5):907-15.
    View in: PubMed
    Score: 0.096
  32. Case-control study of body size and breast cancer risk in Nigerian women. Am J Epidemiol. 2010 Sep 15; 172(6):682-90.
    View in: PubMed
    Score: 0.095
  33. Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat. 2010 Dec; 124(3):857-61.
    View in: PubMed
    Score: 0.095
  34. Searching for large genomic rearrangements of the BRCA1 gene in a Nigerian population. Breast Cancer Res Treat. 2010 Nov; 124(2):573-7.
    View in: PubMed
    Score: 0.094
  35. Estrogen deprivation therapy and colon cancer risk in breast cancer patients. Breast J. 2010 Jan-Feb; 16(1):110-2.
    View in: PubMed
    Score: 0.090
  36. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009 Sep 20; 27(27):4515-21.
    View in: PubMed
    Score: 0.089
  37. Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States. J Clin Oncol. 2009 Mar 10; 27(8):1184-90.
    View in: PubMed
    Score: 0.085
  38. Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry. Fam Cancer. 2009; 8(1):15-22.
    View in: PubMed
    Score: 0.083
  39. Family history of pancreatic cancer in a high-risk cancer clinic: implications for risk assessment. J Genet Couns. 2008 Aug; 17(4):365-72.
    View in: PubMed
    Score: 0.082
  40. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med. 2008 Mar; 10(3):161-166.
    View in: PubMed
    Score: 0.080
  41. Parity and breastfeeding are protective against breast cancer in Nigerian women. Br J Cancer. 2008 Mar 11; 98(5):992-6.
    View in: PubMed
    Score: 0.080
  42. Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat. 2008 Sep; 111(1):113-20.
    View in: PubMed
    Score: 0.078
  43. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in Africans. Breast Cancer Res Treat. 2008 Jul; 110(2):367-76.
    View in: PubMed
    Score: 0.078
  44. UDP-Glucuronosyltransferase 1A1 gene polymorphisms and total bilirubin levels in an ethnically diverse cohort of women. Drug Metab Dispos. 2007 Aug; 35(8):1254-61.
    View in: PubMed
    Score: 0.076
  45. Correlates of depressive symptoms among women seeking cancer genetic counseling and risk assessment at a high-risk cancer clinic. J Genet Couns. 2006 Aug; 15(4):267-76.
    View in: PubMed
    Score: 0.072
  46. BRCA2 mutation and the risk of hematologic malignancy. Leuk Lymphoma. 2006 Apr; 47(4):765-7.
    View in: PubMed
    Score: 0.070
  47. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 2005 Dec 01; 65(23):10692-9.
    View in: PubMed
    Score: 0.069
  48. Breast cancer and race: a rising tide does not lift all boats equally. Perspect Biol Med. 2005; 48(1 Suppl):S166-75.
    View in: PubMed
    Score: 0.064
  49. Benign breast disease and breast cancer risk in African women: a case-control study. Cancer Causes Control. 2024 May; 35(5):787-798.
    View in: PubMed
    Score: 0.060
  50. Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 2024 Apr 15; 130(8):1210-1220.
    View in: PubMed
    Score: 0.060
  51. Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a BRCA1 or BRCA2 Mutation. Cancer Res Commun. 2023 11 28; 3(11):2420-2429.
    View in: PubMed
    Score: 0.060
  52. Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial. JAMA Oncol. 2023 Nov 01; 9(11):1547-1555.
    View in: PubMed
    Score: 0.059
  53. Obesity and height in urban Nigerian women with breast cancer. Ann Epidemiol. 2003 Jul; 13(6):455-61.
    View in: PubMed
    Score: 0.058
  54. Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database. JAMA Oncol. 2023 04 01; 9(4):500-510.
    View in: PubMed
    Score: 0.057
  55. Response to Treatment, Racial and Ethnic Disparity, and Survival in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy in the US. JAMA Netw Open. 2023 03 01; 6(3):e235834.
    View in: PubMed
    Score: 0.057
  56. Validation of the Nigerian Breast Cancer Study Model for Predicting Individual Breast Cancer Risk in Cameroon and Uganda. Cancer Epidemiol Biomarkers Prev. 2023 01 09; 32(1):98-104.
    View in: PubMed
    Score: 0.056
  57. The risks of cancer in older women with BRCA pathogenic variants: How far have we come? Cancer. 2023 03 15; 129(6):901-907.
    View in: PubMed
    Score: 0.056
  58. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res. 2002 Mar 01; 62(5):1481-8.
    View in: PubMed
    Score: 0.053
  59. Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center. Ann Surg Oncol. 2022 Feb; 29(2):1423-1432.
    View in: PubMed
    Score: 0.051
  60. The impact of coronavirus disease 2019 on the quality of life and treatment disruption of patients with breast cancer in a multiethnic cohort. Cancer. 2021 11 01; 127(21):4072-4080.
    View in: PubMed
    Score: 0.051
  61. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet. 2001 Mar; 38(3):159-64.
    View in: PubMed
    Score: 0.049
  62. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun. 2021 02 17; 12(1):1078.
    View in: PubMed
    Score: 0.049
  63. Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients. Breast Cancer Res. 2021 02 04; 23(1):18.
    View in: PubMed
    Score: 0.049
  64. A case of pulmonary toxicity associated with G-CSF and doxorubicin administration. Ann Hematol. 2001 Feb; 80(2):121-3.
    View in: PubMed
    Score: 0.049
  65. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2020 12; 159(3):820-826.
    View in: PubMed
    Score: 0.048
  66. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1355-1362.
    View in: PubMed
    Score: 0.048
  67. Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet. 2000 Aug; 107(2):186-91.
    View in: PubMed
    Score: 0.047
  68. Protein truncating BRCA1 and BRCA2 mutations in African women with pre-menopausal breast cancer. Hum Genet. 2000 Aug; 107(2):192-4.
    View in: PubMed
    Score: 0.047
  69. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Sci Rep. 2020 06 16; 10(1):9688.
    View in: PubMed
    Score: 0.047
  70. Susceptibility gene for familial acute myeloid leukemia associated with loss of 5q and/or 7q is not localized on the commonly deleted portion of 5q. Genes Chromosomes Cancer. 2000 Jun; 28(2):164-72.
    View in: PubMed
    Score: 0.047
  71. Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
    View in: PubMed
    Score: 0.047
  72. Care Coordination for Breast Cancer Survivors in Urban Underserved Communities: Will Treatment Summaries and Survivorship Care Plans Be Enough? J Racial Ethn Health Disparities. 2020 06; 7(3):577-583.
    View in: PubMed
    Score: 0.046
  73. Prevalence of Inherited Mutations in Breast Cancer Predisposition Genes among Women in Uganda and Cameroon. Cancer Epidemiol Biomarkers Prev. 2020 02; 29(2):359-367.
    View in: PubMed
    Score: 0.045
  74. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J Clin Oncol. 2020 03 01; 38(7):674-685.
    View in: PubMed
    Score: 0.045
  75. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Res. 2020 02 01; 80(3):624-638.
    View in: PubMed
    Score: 0.045
  76. Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer Med. 2019 09; 8(12):5609-5618.
    View in: PubMed
    Score: 0.044
  77. N-acetyltransferase 2 enzyme genotype-phenotype discordances in both HIV-negative and HIV-positive Nigerians. Pharmacogenet Genomics. 2019 07; 29(5):106-113.
    View in: PubMed
    Score: 0.044
  78. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2019 07; 121(2):180-192.
    View in: PubMed
    Score: 0.044
  79. Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019 Jun; 175(2):443-449.
    View in: PubMed
    Score: 0.043
  80. Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. Br J Cancer. 2019 02; 120(4):398-403.
    View in: PubMed
    Score: 0.043
  81. Identification of novel common breast cancer risk variants at the 6q25 locus among Latinas. Breast Cancer Res. 2019 01 14; 21(1):3.
    View in: PubMed
    Score: 0.043
  82. Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study. Clin Genet. 2019 02; 95(2):293-301.
    View in: PubMed
    Score: 0.042
  83. Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy? Cancer. 2019 01 15; 125(2):213-222.
    View in: PubMed
    Score: 0.042
  84. Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results. J Natl Cancer Inst. 2018 09 01; 110(9):985-993.
    View in: PubMed
    Score: 0.041
  85. Predisposition testing for inherited breast cancer. Oncology (Williston Park). 1998 Aug; 12(8):1227-41; discussion 1241-2.
    View in: PubMed
    Score: 0.041
  86. CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Cancer Epidemiol Biomarkers Prev. 2018 11; 27(11):1364-1370.
    View in: PubMed
    Score: 0.041
  87. Genetic variation in the Hippo pathway and breast cancer risk in women of African ancestry. Mol Carcinog. 2018 10; 57(10):1311-1318.
    View in: PubMed
    Score: 0.041
  88. Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. Genes Chromosomes Cancer. 1998 May; 22(1):72-8.
    View in: PubMed
    Score: 0.041
  89. Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst. 2018 02 01; 110(2).
    View in: PubMed
    Score: 0.040
  90. Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry. Breast Cancer Res Treat. 2018 Apr; 168(3):703-712.
    View in: PubMed
    Score: 0.040
  91. Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. JAMA Oncol. 2017 12 01; 3(12):1654-1662.
    View in: PubMed
    Score: 0.039
  92. Genetic variation in the vitamin D related pathway and breast cancer risk in women of African ancestry in the root consortium. Int J Cancer. 2018 01 01; 142(1):36-43.
    View in: PubMed
    Score: 0.039
  93. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am. 1997 Jul-Aug; 3(4):230-7.
    View in: PubMed
    Score: 0.038
  94. Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States. JAMA Oncol. 2017 Jul 01; 3(7):928-935.
    View in: PubMed
    Score: 0.038
  95. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017 07 01; 109(7).
    View in: PubMed
    Score: 0.038
  96. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
    View in: PubMed
    Score: 0.038
  97. Recurrent germ-line BRCA1 mutations in extended African American families with early-onset breast cancer. Am J Hum Genet. 1997 May; 60(5):1233-6.
    View in: PubMed
    Score: 0.038
  98. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol. 2017 Jul 10; 35(20):2240-2250.
    View in: PubMed
    Score: 0.038
  99. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine. Blood. 1996 Sep 15; 88(6):2354-5.
    View in: PubMed
    Score: 0.036
  100. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34.
    View in: PubMed
    Score: 0.036
  101. Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry. Hum Genet. 2016 10; 135(10):1145-59.
    View in: PubMed
    Score: 0.036
  102. Familial myeloid leukemia associated with loss of the long arm of chromosome 5. Leukemia. 1996 Apr; 10(4):669-74.
    View in: PubMed
    Score: 0.035
  103. An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population. J Racial Ethn Health Disparities. 2017 04; 4(2):140-148.
    View in: PubMed
    Score: 0.035
  104. Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect. Cancer. 2016 06 15; 122(12):1913-20.
    View in: PubMed
    Score: 0.035
  105. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016 Feb 09; 18(1):15.
    View in: PubMed
    Score: 0.035
  106. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. 2016 Jan 15; 122(2):304-11.
    View in: PubMed
    Score: 0.034
  107. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst. 2016 Feb; 108(2).
    View in: PubMed
    Score: 0.034
  108. Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. Blood. 1995 Sep 01; 86(5):1931-8.
    View in: PubMed
    Score: 0.034
  109. Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome. Gastroenterology. 2015 Nov; 149(6):1446-53.
    View in: PubMed
    Score: 0.034
  110. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. JAMA Oncol. 2015 Jun; 1(3):306-13.
    View in: PubMed
    Score: 0.033
  111. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015 Apr 07; 313(13):1347-61.
    View in: PubMed
    Score: 0.033
  112. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2014 Dec 31; 16(6):3416.
    View in: PubMed
    Score: 0.032
  113. Heterogeneity in hormone-receptor status and survival outcomes among women with synchronous and metachronous bilateral breast cancers. Breast. 2015 Apr; 24(2):131-6.
    View in: PubMed
    Score: 0.032
  114. Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population. Cancer. 2015 Apr 01; 121(7):1071-8.
    View in: PubMed
    Score: 0.032
  115. National survey of US oncologists' knowledge, attitudes, and practice patterns regarding herb and supplement use by patients with cancer. J Clin Oncol. 2014 Dec 20; 32(36):4095-101.
    View in: PubMed
    Score: 0.032
  116. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014 Nov; 148(2):397-406.
    View in: PubMed
    Score: 0.032
  117. Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study. Breast Cancer Res. 2014; 16(4):424.
    View in: PubMed
    Score: 0.031
  118. Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014 Jul; 146(2):421-7.
    View in: PubMed
    Score: 0.031
  119. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet. 2014 04; 10(4):e1004256.
    View in: PubMed
    Score: 0.031
  120. Breast cancer detected on an incident (second or subsequent) round of screening MRI: MRI features of false-negative cases. AJR Am J Roentgenol. 2013 Nov; 201(5):1155-63.
    View in: PubMed
    Score: 0.030
  121. Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst. 2013 Sep 18; 105(18):1365-72.
    View in: PubMed
    Score: 0.029
  122. MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency. Tumour Biol. 2013 Dec; 34(6):3945-58.
    View in: PubMed
    Score: 0.029
  123. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2013 May; 139(1):145-53.
    View in: PubMed
    Score: 0.029
  124. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 2013; 9(3):e1003212.
    View in: PubMed
    Score: 0.028
  125. Relationship between household air pollution from biomass smoke exposure, and pulmonary dysfunction, oxidant-antioxidant imbalance and systemic inflammation in rural women and children in Nigeria. Glob J Health Sci. 2013 Mar 18; 5(4):28-38.
    View in: PubMed
    Score: 0.028
  126. Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. Carcinogenesis. 2013 Jul; 34(7):1520-8.
    View in: PubMed
    Score: 0.028
  127. Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res Treat. 2013 Feb; 138(1):273-9.
    View in: PubMed
    Score: 0.028
  128. Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. Blood. 1992 Dec 01; 80(11):2873-82.
    View in: PubMed
    Score: 0.028
  129. Classification of breast lesions pre-contrast injection using water resonance lineshape analysis. NMR Biomed. 2013 May; 26(5):569-77.
    View in: PubMed
    Score: 0.028
  130. Computerized analysis of mammographic parenchymal patterns on a large clinical dataset of full-field digital mammograms: robustness study with two high-risk datasets. J Digit Imaging. 2012 Oct; 25(5):591-8.
    View in: PubMed
    Score: 0.028
  131. A genome-wide association study of breast cancer in women of African ancestry. Hum Genet. 2013 Jan; 132(1):39-48.
    View in: PubMed
    Score: 0.027
  132. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10; 30(26):3242-9.
    View in: PubMed
    Score: 0.027
  133. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol. 2012 Apr 20; 30(12):1321-8.
    View in: PubMed
    Score: 0.027
  134. Genetic susceptibility to type 2 diabetes and breast cancer risk in women of European and African ancestry. Cancer Epidemiol Biomarkers Prev. 2012 Mar; 21(3):552-6.
    View in: PubMed
    Score: 0.026
  135. When parents disclose BRCA1/2 test results: their communication and perceptions of offspring response. Cancer. 2012 Jul 01; 118(13):3417-25.
    View in: PubMed
    Score: 0.026
  136. DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy. Mol Carcinog. 2012 Oct; 51 Suppl 1:E83-93.
    View in: PubMed
    Score: 0.026
  137. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62.
    View in: PubMed
    Score: 0.026
  138. Lack of association between common single nucleotide polymorphisms in the TERT-CLPTM1L locus and breast cancer in women of African ancestry. Breast Cancer Res Treat. 2012 Feb; 132(1):341-5.
    View in: PubMed
    Score: 0.026
  139. Clinical implications of ERß methylation on sporadic breast cancers in Chinese women. Med Oncol. 2012 Sep; 29(3):1569-75.
    View in: PubMed
    Score: 0.026
  140. Clinicopathological significance and prognostic value of Xeroderma pigmentosum complementary group C (XPC) expression in sporadic breast cancer patients. Med Oncol. 2012 Sep; 29(3):1543-53.
    View in: PubMed
    Score: 0.026
  141. Non-contrast enhanced MRI for evaluation of breast lesions: comparison of non-contrast enhanced high spectral and spatial resolution (HiSS) images versus contrast enhanced fat-suppressed images. Acad Radiol. 2011 Dec; 18(12):1467-74.
    View in: PubMed
    Score: 0.026
  142. Clinical significance of KISS1 protein expression for brain invasion and metastasis. Cancer. 2012 Apr 15; 118(8):2096-105.
    View in: PubMed
    Score: 0.026
  143. Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res. 2011 Sep 01; 71(17):5792-805.
    View in: PubMed
    Score: 0.025
  144. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 2012 Feb 15; 118(4):908-13.
    View in: PubMed
    Score: 0.025
  145. Performance of Lynch syndrome predictive models in a multi-center US referral population. Am J Gastroenterol. 2011 Oct; 106(10):1822-7; quiz 1828.
    View in: PubMed
    Score: 0.025
  146. Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. Cancer Epidemiol Biomarkers Prev. 2011 Aug; 20(8):1690-702.
    View in: PubMed
    Score: 0.025
  147. A signature of balancing selection in the region upstream to the human UGT2B4 gene and implications for breast cancer risk. Hum Genet. 2011 Dec; 130(6):767-75.
    View in: PubMed
    Score: 0.025
  148. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011 Apr 26; 104(9):1384-92.
    View in: PubMed
    Score: 0.025
  149. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2011 May; 127(1):287-96.
    View in: PubMed
    Score: 0.024
  150. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010 Dec 01; 70(23):9742-54.
    View in: PubMed
    Score: 0.024
  151. Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. J Med Genet. 2011 Jan; 48(1):64-8.
    View in: PubMed
    Score: 0.024
  152. Characterizing early contrast uptake of ductal carcinoma in situ with high temporal resolution dynamic contrast-enhanced MRI of the breast: a pilot study. Phys Med Biol. 2010 Oct 07; 55(19):N473-85.
    View in: PubMed
    Score: 0.024
  153. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat. 2011 Aug; 128(3):703-711.
    View in: PubMed
    Score: 0.024
  154. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010 Sep 01; 304(9):967-75.
    View in: PubMed
    Score: 0.024
  155. Parent opinions regarding the genetic testing of minors for BRCA1/2. J Clin Oncol. 2010 Jul 20; 28(21):3498-505.
    View in: PubMed
    Score: 0.024
  156. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43.
    View in: PubMed
    Score: 0.023
  157. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 2010 Jun; 176(6):2911-20.
    View in: PubMed
    Score: 0.023
  158. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2010 Nov; 124(1):195-203.
    View in: PubMed
    Score: 0.023
  159. Long-term survival of patients with intermediate and high grade lymphoma treated with COMLA/ABP. Leukemia. 1990 Feb; 4(2):127-31.
    View in: PubMed
    Score: 0.023
  160. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Res. 2009 Jul 15; 69(14):5801-10.
    View in: PubMed
    Score: 0.022
  161. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
    View in: PubMed
    Score: 0.021
  162. Glucocorticoid receptor expression in breast cancer associates with older patient age. Breast Cancer Res Treat. 2009 Aug; 116(3):441-7.
    View in: PubMed
    Score: 0.021
  163. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer. 2008 Jul 22; 99(2):371-4.
    View in: PubMed
    Score: 0.020
  164. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2008 Jun; 40(6):703-6.
    View in: PubMed
    Score: 0.020
  165. Genomewide scan for loss of heterozygosity and chromosomal amplification in breast carcinoma using single-nucleotide polymorphism arrays. Cancer Genet Cytogenet. 2008 Apr 15; 182(2):69-74.
    View in: PubMed
    Score: 0.020
  166. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet. 2008 Apr; 82(4):937-48.
    View in: PubMed
    Score: 0.020
  167. Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent. Hum Genet. 2008 Apr; 123(3):247-55.
    View in: PubMed
    Score: 0.020
  168. RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Cancer Res. 2008 Jan 01; 68(1):22-5.
    View in: PubMed
    Score: 0.020
  169. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer. 2007 Dec 15; 121(12):2661-7.
    View in: PubMed
    Score: 0.020
  170. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Jan; 108(1):3-9.
    View in: PubMed
    Score: 0.020
  171. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet. 2007 Dec; 81(6):1186-200.
    View in: PubMed
    Score: 0.020
  172. How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. J Clin Oncol. 2007 Aug 20; 25(24):3705-11.
    View in: PubMed
    Score: 0.019
  173. AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev. 2007 Jul; 16(7):1416-21.
    View in: PubMed
    Score: 0.019
  174. Fractal analysis of mammographic parenchymal patterns in breast cancer risk assessment. Acad Radiol. 2007 May; 14(5):513-21.
    View in: PubMed
    Score: 0.019
  175. Fat suppression with spectrally selective inversion vs. high spectral and spatial resolution MRI of breast lesions: qualitative and quantitative comparisons. J Magn Reson Imaging. 2006 Dec; 24(6):1311-5.
    View in: PubMed
    Score: 0.018
  176. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 2006 Dec; 3(12):e486.
    View in: PubMed
    Score: 0.018
  177. The I1307K APC polymorphism in Ashkenazi Jews with colorectal cancer: clinical and pathologic features. Cancer Genet Cytogenet. 2006 Aug; 169(1):33-8.
    View in: PubMed
    Score: 0.018
  178. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006 Jul 12; 296(2):185-92.
    View in: PubMed
    Score: 0.018
  179. "Why take it if you don't have anything?" breast cancer risk perceptions and prevention choices at a public hospital. J Gen Intern Med. 2006 Jul; 21(7):779-85.
    View in: PubMed
    Score: 0.018
  180. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006 May 01; 118(9):2281-4.
    View in: PubMed
    Score: 0.018
  181. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006 Jun 01; 24(16):2437-43.
    View in: PubMed
    Score: 0.018
  182. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol. 2006 Mar; 7(3):223-9.
    View in: PubMed
    Score: 0.017
  183. High spectral and spatial resolution MRI of breast lesions: preliminary clinical experience. AJR Am J Roentgenol. 2006 Jan; 186(1):30-7.
    View in: PubMed
    Score: 0.017
  184. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer. 2005 Dec 20; 117(6):988-91.
    View in: PubMed
    Score: 0.017
  185. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005 Nov 01; 23(31):7804-10.
    View in: PubMed
    Score: 0.017
  186. Computerized texture analysis of mammographic parenchymal patterns of digitized mammograms. Acad Radiol. 2005 Jul; 12(7):863-73.
    View in: PubMed
    Score: 0.017
  187. A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev. 2005 Jun; 14(6):1534-8.
    View in: PubMed
    Score: 0.017
  188. Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol. 2005 Feb 01; 23(4):685-93.
    View in: PubMed
    Score: 0.016
  189. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005 Jan; 96(1):222-6.
    View in: PubMed
    Score: 0.016
  190. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004 Jun 15; 22(12):2328-35.
    View in: PubMed
    Score: 0.015
  191. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004 Mar 15; 10(6):2029-34.
    View in: PubMed
    Score: 0.015
  192. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004 Mar 15; 22(6):1055-62.
    View in: PubMed
    Score: 0.015
  193. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res. 2004 Jan 15; 10(2):499-507.
    View in: PubMed
    Score: 0.015
  194. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002 Dec 04; 94(23):1773-9.
    View in: PubMed
    Score: 0.014
  195. Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers. Radiology. 2002 Nov; 225(2):519-26.
    View in: PubMed
    Score: 0.014
  196. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002 May 23; 346(21):1616-22.
    View in: PubMed
    Score: 0.013
  197. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope. 2002 Mar; 112(3):472-81.
    View in: PubMed
    Score: 0.013
  198. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics. 2001 Oct; 11(7):635-8.
    View in: PubMed
    Score: 0.013
  199. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol. 2000 Oct 01; 18(19):3360-9.
    View in: PubMed
    Score: 0.012
  200. Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression. Clin Cancer Res. 2000 Oct; 6(10):4043-8.
    View in: PubMed
    Score: 0.012
  201. Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome: beta(2)-glycoprotein I antibodies as a marker of response to therapy. J Clin Apher. 1999; 14(4):171-6.
    View in: PubMed
    Score: 0.011
  202. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998 Jul; 16(7):2417-25.
    View in: PubMed
    Score: 0.010
  203. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst. 1998 May 20; 90(10):761-6.
    View in: PubMed
    Score: 0.010
  204. CDKN2 gene deletion is not found in chronic lymphoid leukaemias of B- and T-cell origin but is frequent in acute lymphoblastic leukaemia. Br J Haematol. 1995 Dec; 91(4):865-70.
    View in: PubMed
    Score: 0.009
  205. Methylthioadenosine phosphorylase deficiency in human non-small cell lung cancers. Cancer Res. 1993 Mar 01; 53(5):1098-101.
    View in: PubMed
    Score: 0.007
  206. Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo-astrocytomas. Genes Chromosomes Cancer. 1992 Nov; 5(4):357-74.
    View in: PubMed
    Score: 0.007
  207. Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11). Genes Chromosomes Cancer. 1990 Jul; 2(2):147-58.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.